This site is intended for healthcare professionals
Cerebellum, Thalamus, Medulla oblongata, Spinal cord and Motor Neuron human under the microscope in Lab. Pink and Purple colours
Transcript

Determining appropriate initial treatment in CIDP

Published:18th Aug 2025

Eduardo Nobile-Orazio (University of Milan, Italy) provides guidance on how to select the most appropriate initial treatment following a CIDP diagnosis. View transcript.

Eduardo Nobile-Orazio, MD, PhD

All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speakers and is not adjusted by Medthority.

I would say what we usually prefer to do if we have a young patient, or a patient with a recent onset, we personally, we prefer to start with immunoglobulin because they're better tolerate and we can treat the patient on day service. And, but of course, you know, that cannot be a general rule because as I mentioned before, an immunoglobulin is a much more expensive than steroids. Of course, in Italy, the cost of one year of steroids will not reach 1,000 euro. 

If you talk about immunoglobulin, we are talking about 40 to 50,000, at least 40 to 50,000 euros. So that is something, you know, you have to consider. And also it depends if you, in Italy we have a social system, you know,? The hospital, the social system pay. In other country might not be that condition. So if you do not have an insurance, so you have to consider this point. But from a clinical point of view, we prefer to use immunoglobulin. Of course, immunoglobulin at the beginning of the patient has to come to the clinic. And if you use steroids. Steroids, it take longer to you to work. So if the patient has a recent disease, you know, they may have to wait three to four months before improving. With immunoglobulin the improvement faster. And so also you stop the progression of the disease from the beginning, but it's more expensive.

Determining appropriate initial treatment in CIDP

This content has been developed independently by Medthority who previously received educational funding from argenx in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.